Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Iron overload is the hallmark of hereditary hemochromatosis and a complication of iron-loading anemias such as β-thalassemia. Treatment can be burdensome and have significant side effects, and new therapeutic options are needed. Iron overload in hereditary hemochromatosis and β-thalassemia intermedia is caused by hepcidin deficiency. Although transgenic hepcidin replacement in mouse models of these diseases prevents iron overload or decreases its potential toxicity, natural hepcidin is prohibitively expensive for human application and has unfavorable pharmacologic properties. Here, we report the rational design of hepcidin agonists based on the mutagenesis of hepcidin and the hepcidin-binding region of ferroportin and computer modeling of their docking. We identified specific hydrophobic/aromatic residues required for hepcidin-ferroportin binding and obtained evidence in vitro that a thiol-disulfide interaction between ferroportin C326 and the hepcidin disulfide cage may stabilize binding. Guided by this model, we showed that 7–9 N-terminal amino acids of hepcidin, including a single thiol cysteine, comprised the minimal structure that retained hepcidin activity, as shown by the induction of ferroportin degradation in reporter cells. Further modifications to increase resistance to proteolysis and oral bioavailability yielded minihepcidins that, after parenteral or oral administration to mice, lowered serum iron levels comparably to those after parenteral native hepcidin. Moreover, liver iron concentrations were lower in mice chronically treated with minihepcidins than those in mice treated with solvent alone. Minihepcidins may be useful for the treatment of iron overload disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Minihepcidins are synthetic hepcidin agonists previously shown to bind ferroportin and induce its endocytosis and proteolysis, thus preventing iron overload in hepcidin-deficient mice (Preza et al., 2011; Ramos et al., 2012).”
From Hepcidin-Induced Hypoferremia Is a Critical Host Defense Mechanism against the Siderophilic Bacterium Vibrio vulnificus (2015) · cites this paper as Preza et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other interactions between FPN and hepcidin are either hydrophobic or depend on hepcidin amide backbone atoms, which is consistent with the relatively high tolerance of amino acid substitutions within hepcidin 40 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“This led to the development of mini-hepcidin analogs containing a minimal core of 7–9 N-terminal amino acids with a single cysteine, which suffice to trigger ferroportin internalization and degradation in cells and mice (Preza et al., 2011).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Preza et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: The Hepcidin-Binding Site on Ferroportin Is Evolutionarily Conserved
De Domenico, I., Nemeth, E., Nelson, J. M., Phillips, J. D., Ajioka, R. S., Kay, M. S., Kushner, J. P., Ganz, T., Ward, D. M., & Kaplan, J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.002 · Cited by 129
Self-citationRetractedHepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Self-citationNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650
Self-citationZDOCK: An initial‐stage protein‐docking algorithm
Chen, R., Li, L., & Weng, Z. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10389 · Cited by 1,393
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
Papanikolaou, G., Samuels, M. E., Ludwig, E. H., MacDonald, M. L. E., Franchini, P. L., Dubé, M.-P., Andres, L., MacFarlane, J., Sakellaropoulos, N., Politou, M., et al. (2004) · Nature Genetics · doi:10.1038/ng1274 · Cited by 974 · cited 1×
“Discussion In hereditary hemochromatosis, hepcidin deficiency is a consequence of destructive mutations in the genes encoding hepcidin (24) or one of its regulators, HFE (3) (most common), transferrin receptor 2 (25), or hemojuvelin (26).”
BackgroundSelf-citationMutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis
Roetto, A., Papanikolaou, G., Politou, M., Alberti, F., Girelli, D., Christakis, J., Loukopoulos, D., & Camaschella, C. (2003) · Nature Genetics · doi:10.1038/ng1053 · Cited by 860 · cited 1×
“Discussion In hereditary hemochromatosis, hepcidin deficiency is a consequence of destructive mutations in the genes encoding hepcidin (24) or one of its regulators, HFE (3) (most common), transferrin receptor 2 (25), or hemojuvelin (26).”
BackgroundSreerama, N., Venyaminov, S. Y. U., & Woody, R. W. (1999) · Protein Science · doi:10.1110/ps.8.2.370 · Cited by 708
Immunoassay for human serum hepcidin
Ganz, T., Olbina, G., Girelli, D., Nemeth, E., & Westerman, M. (2008) · Blood · doi:10.1182/blood-2008-02-139915 · Cited by 688
Self-citationThe RosettaDock server for local protein-protein docking
Lyskov, S., & Gray, J. J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn216 · Cited by 592
Suppression of hepcidin during anemia requires erythropoietic activity
Pak, M., Lopez, M. A., Gabayan, V., Ganz, T., & Rivera, S. (2006) · Blood · doi:10.1182/blood-2006-06-028787 · Cited by 472 · cited 1×
“Nonheme iron concentration was determined as described (44), using”
MethodSelf-citation
Cited by
Items 201–236 of 236
Advances in iron homeostasis and ferromagnetic nanoparticles
Wang, J., An, P., Wang, H., Wu, Q., Fang, X., Min, J., & Wang, F. (2018) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/n972018-00707
Serum Hepcidin Quantification in Stroke in β-Thalassemia and Rheumatoid Arthritis Patients
Manolov, V. (2017) · Austin Journal of Cerebrovascular Disease & Stroke · doi:10.26420/austinjcerebrovascdisstroke.2017.1056 · Cited by 1
“There are a few studies about micro-hepcidin as an alternative of chelation therapy, especially in patients without transfusion therapy [15].”
BackgroundGirelli, D., & Busti, F. (2020) · Haematologica · doi:10.3324/haematol.2020.253393 · Cited by 3
“An alternative approach is represented by the production of long-acting molecules, collectively called “minihepcidins”.(15) Minihepcidins are synthetic peptides containing the minimal N-terminal sequence (7 to 9 amino acids) of hepcidin still able to bind ferroportin and induce its degradation, further engineered to b…”
BackgroundCurrent Perspective of Beta Thalassemia and Its Treatment StrategiesPreprint
Ali, S., Mumtaz, S., Shakir, H. A., Tahir, H. M., & Mughal, T. A. (2019) · Preprints.org · doi:10.20944/preprints201907.0277.v1 · Cited by 1
“been recommended as prospective useful mediators in severe beta thalassemic patients [24].”
BackgroundIron Homeostasis: Hepcidin Regulation
Camaschella, C., & Silvestri, L. (2004) · Wiley eBooks · doi:10.1002/9781119951438.eibc2131
Iron: Molecular Basis of Hemochromatosis
Schmidt, P. J. (2004) · Wiley eBooks · doi:10.1002/9781119951438.eibc2137
Spongious therapy of iron overload with hipcidin overexpressed macrophages
(2016) · Macrophage · doi:10.14800/macrophage.1107
“Page 2 of 3 Iron overload can be treated with phlebotomy and iron chelators ([9]).”
BackgroundWhite, J. A. (2015) · Journal of Cancer Prevention & Current Research · doi:10.15406/jcpcr.2015.03.00077 · Cited by 1
“Minihepcidins: Minihepcidins are peptide-based agonists, which are designed based on the region of hepcidin that interacts with ferroportin [117].”
BackgroundHepcidin knockout mice as a model of iron-overload associated liver disease
Lunová, M., Vaulont, S., Haybaeck, J., Lackner, K., Adler, G., & Strnad, P. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0030-1269571
Dutta, G. K., Thakur, K., Mandal, S., & Dash, A. K. (2014)
Taniguchi, R., & Nureki, O. (2016) · Springer eBooks · doi:10.1007/978-4-431-56068-5_6
Tandara, L. (2016) · Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu)
Schmidt, P. J., Toudjarska, I., Sendamarai, A. K., Racie, T., Milstein, S., Bettencourt, B. R., Hettinger, J. L., Bumcrot, D. A., & Fleming, M. D. (2017)
Hemochromatosis and Iron Storage Disorders
Kowdley, K. V., & Handa, P. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch30
Milenković, J., Stojanović, D. R., & Najdanović, J. G. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94081
The Use of Ferritin as a Carrier of Peptides and Its Application for Hepcidin
Boumaiza, M., Rourou, S., Arosio, P., & Marzouki, M. N. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94408
Hepcidin antimicrobial peptide
Kanamori, Y., & Funaba, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820649-2.00154-6
Identification and analysis of genetic and chemical modulators of iron metabolism
Hawula, Z. J. (2021) · Queensland University of Technology · doi:10.5204/thesis.eprints.225904 · Cited by 1
Iron Uptake in Host Defense Against Pneumonia
Michels, K. R. (2017) · doi:10.18130/v3465h
The Relationshıp Between Ghrelin And Iron Metabolism In Beta Thassemia Major PatientsPreprint
Sarkaya, N. C., Kurtoğlu, A. U., & Göçer, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3180782/v1
The Relationship Between Ghrelin and Iron Metabolism in Beta Thassemia Major PatientsPreprint
Sarkaya, N. C., Kurtoğlu, A. U., & Göçer, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3163185/v1
Characterization and Clinical Assessment of a Peculiar Case of Hemolytic Anemia
Castelgrande, F., Viola, G., Calabrese, C., Iozzo, M., Massoud, R., Pieri, M., Minieri, M., Adorno, G., Bernardini, S., & Terrinoni, A. (2024) · Journal of Hematology · doi:10.14740/jh1204 · Cited by 1
Intestine-Specific Ferroportin Ablation Rescues from Systemic Iron Overload in Mice
Castillo, C., GIM, S. C. M. M. F. F., & Das, N. K. (2026) · Nutrients · doi:10.3390/nu18020352
“Elevating hepcidin would reduce intestinal Fpn1, limit dietary iron absorption, and promote safe macrophage sequestration, which is consistent with the previously reported benefits of hepcidin agonists and mimetics in preclinical models [17,39].”
Surcharges en fer rares d’origine génétique : caractérisation clinique, fonctionnelle, et biologique
Bardou‐Jacquet, E. (2013) · theses.fr (ABES) · doi:10.70675/99eb557fz5edcz4fdezbd26z84ca08eab5aa
Le rôle de l'érythroferrone dans la régulation du métabolisme du fer
Sardo, U. (2020) · theses.fr (ABES) · doi:10.70675/d03e67aczc44bz4af9z8fa1zef080668f44f
Ferroportin at the Crossroads of Iron Biology: Disease, Regulation and Modulation
Rathnayake, P. H., Ryan, N. E., Atkins, R., Wallace, D. F., & Subramaniam, V. N. (2026) · Biomolecules · doi:10.3390/biom16071066
“Mini-hepcidins, like Hep9 derivatives, are small, engineered peptides that mimic the active N-terminal region of native hepcidin [95].”
Costa, A., Pilo, F., & Breccia, M. (2026) · Blood Reviews · doi:10.1016/j.blre.2026.101420 · Cited by 1
Genetics of Hereditary Hemochromatosis
Alamgir, M., Sohal, A., & Kowdley, K. V. (2026) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2026.05.015
2026 Update on Clinical Trials in β‐Thalassemia
Musallam, K. M., Locatelli, F., Algeri, M., Cappellini, M. D., & Taher, A. T. (2026) · American Journal of Hematology · doi:10.1002/ajh.70472 · Cited by 1
Iron Homeostasis and Liver Diseases
Yang, P., Shi, Z. X., Huang, Q., Tu, Z., Sun, Y., Wang, L., & Wei, Y. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71412
BindingDB Entry 50006544: Small lipidated anti-obesity compounds derived from neuromedin U.
BindingDB (2020) · UC San Diego · doi:10.7270/q26h4mff
BindingDB Entry 50045414: Thiol-derivatized minihepcidins retain biological activity.
BindingDB (2016) · UC San Diego · doi:10.7270/q28w3fz4
BindingDB Entry 50046601: Small cyclic agonists of iron regulatory hormone hepcidin.
BindingDB (2016) · UC San Diego · doi:10.7270/q2cr5w6z
Metadata
- Authors
- Preza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., Sharma, S., Waring, A., Ganz, T., & Nemeth, E.
- Affiliations
- University of California, Los Angeles (US)
- Columbia University (US)
- California Institute of Technology (US)
- University of California, Irvine (US)
- Corresponding author
- Nemeth, Elizabeta
- Venue
- Journal of Clinical Investigation
- Published
- 2011-12-01
- Volume
- 121
- Issue
- 12
- Pages
- 4880-4888
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3225996
- OpenAlex
- W2146444665
- Cited by
- 234
- References
- 45
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 11 · 2023: 15 · 2022: 18 · 2021: 12 · 2020: 16 · 2019: 15 · 2018: 12 · 2017: 29 · 2016: 18 · 2015: 20 · 2014: 13 · 2013: 22 · 2012: 17
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Funders
- National Institutes of Health
- Center for AIDS Research, University of Washington
- University of California, Irvine
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK065029, R01DK082717)
- Jonsson Comprehensive Cancer Center
- California NanoSystems Institute
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- iron overload, hereditary hemochromatosis, beta-thalassemia intermedia, ferroportin, oral bioavailability, serum iron, liver iron, peptide design
- MeSH terms
- Ferroportin, Amino Acid Sequence, Animals, Binding Sites, Computer Simulation, Cysteine, Drug Evaluation, Preclinical, Humans, Iron, Liver, Models, Molecular, Molecular Sequence Data, Peptide Fragments, Protein Conformation, Structure-Activity Relationship, Drug Design, Mutagenesis, Site-Directed, Iron Overload, Amino Acid Substitution, Antimicrobial Cationic Peptides, Protein Interaction Mapping, Cation Transport Proteins, Mice, Hydrophobic and Hydrophilic Interactions, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.